|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACBD5 |
Gene summary for ACBD5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACBD5 | Gene ID | 91452 |
| Gene name | acyl-CoA binding domain containing 5 | |
| Gene Alias | RDLKD | |
| Cytomap | 10p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006914 | UniProtAcc | B7Z2A7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91452 | ACBD5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.14e-09 | 5.12e-01 | -0.0811 |
| 91452 | ACBD5 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.53e-11 | 4.20e-01 | -0.1954 |
| 91452 | ACBD5 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.42e-04 | 6.46e-01 | -0.2602 |
| 91452 | ACBD5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.04e-09 | 5.46e-01 | -0.059 |
| 91452 | ACBD5 | A015-C-203 | Human | Colorectum | FAP | 3.72e-06 | -1.08e-01 | -0.1294 |
| 91452 | ACBD5 | A001-C-108 | Human | Colorectum | FAP | 1.34e-03 | -4.52e-02 | -0.0272 |
| 91452 | ACBD5 | A002-C-205 | Human | Colorectum | FAP | 7.96e-04 | -1.35e-01 | -0.1236 |
| 91452 | ACBD5 | A015-C-006 | Human | Colorectum | FAP | 2.29e-02 | -1.98e-01 | -0.0994 |
| 91452 | ACBD5 | A015-C-106 | Human | Colorectum | FAP | 7.07e-03 | -1.39e-01 | -0.0511 |
| 91452 | ACBD5 | A002-C-114 | Human | Colorectum | FAP | 7.87e-03 | -1.30e-01 | -0.1561 |
| 91452 | ACBD5 | A015-C-104 | Human | Colorectum | FAP | 6.81e-09 | -1.10e-01 | -0.1899 |
| 91452 | ACBD5 | A001-C-014 | Human | Colorectum | FAP | 4.79e-03 | -1.56e-01 | 0.0135 |
| 91452 | ACBD5 | A002-C-016 | Human | Colorectum | FAP | 8.81e-06 | -8.42e-02 | 0.0521 |
| 91452 | ACBD5 | A002-C-116 | Human | Colorectum | FAP | 5.22e-07 | -1.20e-01 | -0.0452 |
| 91452 | ACBD5 | A018-E-020 | Human | Colorectum | FAP | 3.03e-02 | -1.24e-01 | -0.2034 |
| 91452 | ACBD5 | F034 | Human | Colorectum | FAP | 6.45e-06 | -1.21e-01 | -0.0665 |
| 91452 | ACBD5 | CRC-3-11773 | Human | Colorectum | CRC | 1.38e-02 | -1.24e-01 | 0.2564 |
| 91452 | ACBD5 | LZE4T | Human | Esophagus | ESCC | 1.18e-11 | 3.75e-01 | 0.0811 |
| 91452 | ACBD5 | LZE5T | Human | Esophagus | ESCC | 2.40e-02 | 3.92e-01 | 0.0514 |
| 91452 | ACBD5 | LZE24T | Human | Esophagus | ESCC | 1.18e-08 | 2.75e-01 | 0.0596 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACBD5 | SNV | Missense_Mutation | novel | c.439N>G | p.Tyr147Asp | p.Y147D | Q5T8D3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-22-1016-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ACBD5 | SNV | Missense_Mutation | novel | c.937N>G | p.Ser313Ala | p.S313A | Q5T8D3 | protein_coding | tolerated(0.29) | benign(0.067) | TCGA-43-2576-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| ACBD5 | SNV | Missense_Mutation | novel | c.271G>A | p.Gly91Arg | p.G91R | Q5T8D3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-94-8491-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
| ACBD5 | SNV | Missense_Mutation | novel | c.1550N>G | p.Tyr517Cys | p.Y517C | Q5T8D3 | protein_coding | deleterious(0.04) | probably_damaging(0.969) | TCGA-CR-7367-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | SD |
| ACBD5 | SNV | Missense_Mutation | c.1321N>T | p.Ala441Ser | p.A441S | Q5T8D3 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-EJ-5525-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD | |
| ACBD5 | SNV | Missense_Mutation | rs768365855 | c.962N>G | p.Asn321Ser | p.N321S | Q5T8D3 | protein_coding | tolerated(0.81) | benign(0) | TCGA-EJ-A8FN-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
| ACBD5 | SNV | Missense_Mutation | novel | c.480N>A | p.Asp160Glu | p.D160E | Q5T8D3 | protein_coding | deleterious(0.01) | possibly_damaging(0.539) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACBD5 | SNV | Missense_Mutation | novel | c.1232N>C | p.Gly411Ala | p.G411A | Q5T8D3 | protein_coding | deleterious(0) | possibly_damaging(0.742) | TCGA-RD-A7BT-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| ACBD5 | SNV | Missense_Mutation | rs759217853 | c.1165N>A | p.Gly389Arg | p.G389R | Q5T8D3 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-VQ-A91E-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
| ACBD5 | insertion | Frame_Shift_Ins | novel | c.177dupG | p.Asn60GlufsTer9 | p.N60Efs*9 | Q5T8D3 | protein_coding | TCGA-CG-5725-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | docetaxel | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |